Abstract
A considerable amount of data supports a 1.8-7.4-fold increased mortality associated with Cushing’s syndrome (CS). This is attributed to a high occurrence of several cardiovascular disease (CVD) risk factors in CS [e.g. adiposity, arterial hypertension (AHT), dyslipidaemia and type 2 diabetes mellitus (T2DM)]. Therefore, practically all patients with CS have the metabolic syndrome (MetS), which represents a high CVD risk. Characteristically, despite a relatively young average age, numerous patients with CS display a 'high' or 'very high' CVD risk (i.e. risk of a major CVD event >20% in the following 10 years). Although T2DM is listed as a condition with a high CVD risk, CS is not, despite the fact that a considerable proportion of the CS population will develop T2DM or impaired glucose tolerance. CS is also regarded as a risk factor for aortic dissection in current guidelines. This review considers the evidence supporting listing CS among high CVD risk conditions.
Keywords: Cushing's syndrome, diabetes mellitus, arterial hypertension, metabolic syndrome, cardiovascular risk factors.
[1]
Căpăţînă C, Baciu I, Greere D, Caragheorgheopol A, Poiană C. Secondary diabetes mellitus in patients with endogenous Cushing’s syndrome - clinical characteristics at diagnosis. Rom J Diabetes Nutr Metab Dis 2018; 25(1): 77-81.
[2]
Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA /SCAI/SIR/ STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. Circulation 2010; 121(13): e266-369.
[4]
Magiakou MA, Smyrnaki P, Chrousos GP. Hypertension in Cushing’s syndrome. Best Pract and Res Clin Endocrinol Metab 2006; 20: 467-82.
[5]
Miljic P, Miljic D, Cain JW, Korbonits M, Popovic V. Pathogenesis of vascular complications in Cushing’s syndrome. Hormones 2012; 11(1): 21-30.
[6]
Wei L, MacDonald TM, Walker B. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141(10): 764-70.
[7]
Pivonello R, Faggiano A, Lombardi G, Colao A. The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol Metab Clin 2017; 34(2): 327-39.
[8]
De Leo M, Pivonello R, Auriemma RS, et al. Cardiovascular disease in Cushing’s syndrome: Heart versus vasculature. Neuroendocrinology 2010; 92(Suppl. 1): 50-4.
[9]
Loriaux L. Diagnosis and differential diagnosis of Cushing’s syndrome. N Engl J Med 2017; 376: 1451-9.
[10]
Giordano R, Picu A, Marinazzo E, et al. Metabolic and cardiovascular outcomes in patients with Cushing’s syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf) 2011; 75(3): 354-60.
[11]
Scaroni C, Zilio M, Foti M, Boscaro M. Glucose metabolism abnormalities in cushing syndrome: From molecular basis to clinical management. Endocr Rev 2017; 38(3): 189-219.
[12]
Perk J, De Backer G, Gohlke H, et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33(13): 1635-701.
[13]
Singh Y, Menon A, Kotwal N. Endocrine hypertension - Cushing′s syndrome. Indian J Endocrinol Metab 2011; 15(8): 313.
[14]
Clutter WE. Screening for Cushing’s syndrome in an era of epidemic obesity. Mo Med 2011; 108(2): 104-6.
[15]
Steptoe A, Marmot M. Socioeconomic status and coronary heart disease: A Psychobiological Perspective. Aging Health Public Policy 2005; 30(Suppl.): 133-50.
[16]
Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing’s disease over 50 years in stoke-on-trent, UK: Audit and meta-analysis of literature. J Clin Endocrinol Metab 2011; 96(3): 632-42.
[17]
Bolland MJ, Holdaway IM, Berkeley JE, et al. Mortality and morbidity in Cushing’s syndrome in New Zealand. Clin Endocrinol (Oxf) 2011; 75(4): 436-42.
[18]
Martins LC, Conceicao FL, Muxfeldt ES, Salles GF. Prevalence and associated factors of subclinical hypercortisolism in patients with resistant hypertension. J Hypertens 2012; 30(5): 967-73.
[19]
Kastelan D, Dusek T, Kraljevic I, Aganovic I. Hypercoagulable state in Cushing’s syndrome is reversible following remission. Clin Endocrinol (Oxf) 2013; 78(1): 102-6.
[20]
Bose M, Oliván B, Laferrère B. Stress and obesity: The role of the hypothalamic-pituitary-adrenal axis in metabolic disease. Curr Opin Endocrinol Diabetes Obes 2009; 16(5): 340-6.
[21]
Bayram NA, Ersoy R, Sen DO, et al. The relationship between aortic stiffness and left ventricular function in patients with Cushing’s disease: Aortic stiffness in Cushing’s disease. Endocrine 2010; 37(2): 280-5.
[22]
Jyotsna VP, Naseer A, Sreenivas V, Gupta N, Deepak KK. Effect of Cushing’s syndrome - Endogenous hypercortisolemia on cardiovascular autonomic functions. Auton Neurosci Basic Clin 2011; 160(1-2): 99-102.
[23]
Valassi E, Santos A, Yaneva M, et al. The European registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 2011; 165(3): 383-92.
[24]
Valassi E, Crespo I, Santos A, Webb SM. Clinical consequences of Cushing’s syndrome. Pituitary 2012; 15(3): 319-29.
[25]
Guaraldi F, Salvatori R. Cushing syndrome: Maybe not so uncommon of an endocrine disease. J Am Board Fam Med 2012; 25(2): 199-208.
[26]
Whitworth JA, Mangos GJ, Kelly JJ. Cushing, cortisol, and cardiovascular disease. Hypertension 2000; 36(5): 912-6.
[27]
Abdu T. Endothelial dysfunction in endocrine disease. Trends Endocrinol Metab 2001; 12(6): 257-65.
[28]
Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002; 87(11): 4872-8.
[29]
Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88(12): 5593-602.
[30]
Kirilov G, Tomova A, Dakovska L, Kumanov P, Shinkov A, Alexandrov AS. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing’s syndrome. Eur J Endocrinol 2003; 149(6): 549-53.
[31]
Arnaldi G, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing’s syndrome. Pituitary 2004; 7(4): 253-6.
[32]
Girod JP, Brotman DJ. Does altered glucocorticoid homeostasis increase cardiovascular risk? Cardiovasc Res 2004; 64: 217-26.
[33]
Baid S, Nieman LK. Glucocorticoid excess and hypertension. Curr Hypertens Rep 2004; 6(6): 493-9.
[34]
Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004; 61(6): 768-77.
[35]
Terzolo M, Pia A, Reimondo G. Subclinical Cushing’s syndrome: Definition and management. Clin Endocrinol 2012; 76: 12-8.
[36]
Ayala A, Chrousos G. Cushing’s Syndrome. In: Linos D, van Heerden JA, Eds. Adrenal Glands: Diagnostic Aspects and Surgical Therapy. Springer-Verlag: Berlin, Heidelberg 2005; pp. 57-66.
[37]
Whitworth JA, Williamson PM, Mangos G, Kelly JJ. Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag 2005; 1: 291-9.
[38]
Sacerdote A, Weiss K, Tran T, Rokeya Noor B, McFarlane SI. Hypertension in patients with Cushing’s disease: pathophysiology, diagnosis, and management. Curr Hypertens Rep 2005; 7(3): 212-8.
[40]
Beuschlein F, Reincke M. Subclinical Cushing’s syndrome. Adrenal Glands: Diagn Aspects Surg Ther 2005; 29(Suppl.): 67-74.
[41]
Ross EJ, Linch DC. Cushing’s syndrome-killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 320(8299): 646-9.
[42]
Tsuiki M, Tanabe A, Takagi S, Naruse M, Takano K. Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing’s syndrome. Endocr J 2008; 55(4): 737-45.
[43]
Shibli-Rahhal A, Van Beek M, Schlechte JA. Cushing’s syndrome. Clin Dermatol 2006; 24(4): 260-5.
[44]
Erbil Y, Ademoğlu E, Ozbey N, et al. Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J Surg 2006; 30(9): 1665-71.
[45]
Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet 2006; 367(9522): 1605-17.
[47]
Janßen OE, Mann K, Erbel R. Endocrine disorders and the heart. Internist (Berl) 2007; 48(3): 246-54.
[48]
Lavis VR, Picolos MK, Willerson JT. Endocrine Disorders and the Heart. In: Willerson JT, Wellens HJJ, Cohn JN, Holmes DR, Eds. Cardiovascular Medicine. Springer London: London 2007; pp. 2295-330.
[49]
Waeber B, Brunner H-R, Burnier M, Cohn JN. Hypertension. In: Willerson JT, Wellens HJJ, Cohn JN, Holmes DR, Eds. Cardiovascular Medicine. Springer London: London 2007; pp. 1833-70.
[50]
Thomson SP, Stump CS, Kurukulasuriya LR, Sowers JR. Adrenal steroids and the metabolic syndrome. Curr Hypertens Rep 2007; 9: 512-9.
[51]
Calhoun DA, Jones D, Textor S, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment. Hypertension 2008; 51(6): 1403-19.
[52]
Cuttica CM, Del Monte P, Cardillo T, et al. Cushing’s syndrome as a cause of secondary obesity and metabolic syndrome: a case report. Med J Nutrition Metab 2009; 2(3): 225.
[53]
Kantorovich V, Koch CA, Chrousos GP. Hypertension in Patients with Cushing’s Syndrome. In: Koch CA, Chrousos GP, Eds. Endocrine Hypertension: Underlying Mechanisms and Therapy. Humana Press: Totowa, NJ 2013; pp. 51-67.
[54]
Young W, Calhoun D, Lenders J, Stowasser M, Textor S. Screening for Endocrine Hypertension. Endocr Rev 2017; 38(2): 103-22.
[55]
Ahmed MI, Pisoni R, Calhoun DA. Current options for the treatment of resistant hypertension. Expert Rev Cardiovasc Ther 2009; 7(11): 1385-93.
[56]
Avenatti E, Rebellato A, Iannaccone A, et al. Left ventricular geometry and 24-h blood pressure profile in Cushing’s syndrome. Endocrine 2017; 55(2): 547-54.
[57]
Deegan RJ, Furman WR. Cardiovascular Manifestations of Endocrine Dysfunction. J Cardiothorac Vasc Anesth 2017; 25(4): 705-20.
[58]
Williamson PM, Kelly JJ, Whitworth JA. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens Suppl 1996; 14(5): S37-41.
[59]
Dodt C, Wellhöner JP, Schütt M, Sayk F. [Glucocorticoids and hypertension]. Internist (Berl) 2009; 50(1): 36-41.
[60]
Carroll TB, Findling JW. The diagnosis of Cushing’s syndrome. Rev Endocr Metab Disord 2010; 11(2): 147-53.
[61]
De la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57(5): 898-902.
[62]
Stewart PM, Petersenn S. 3 Rationale for treatment and therapeutic options in Cushing’s disease. Best Pract Res Clin Endocrinol Metab 2017; 23: S15-22.
[63]
Londero T, Moreira AM, Leitão C, Ticiana Rodrigues T, Czepielewski M. Diabetes mellitus in Cushing’ syndrome: A systematic review. Endocrine Abstr 2017; 49EP919
[64]
Sharma ST, Nieman LK. Cushing’s syndrome: All variants, detection, and treatment. Endocrinol Metab Clin North Am 2011; 40: 379-91.
[66]
Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: Basic and clinical aspects. Trends Endocrinol Metab 2011; 22: 499-506.
[67]
Schneider HJ, Dimopoulou C, Stalla GK, Reincke M, Schopohl J. Discriminatory value of signs and symptoms in Cushing’s syndrome revisited: What has changed in 30 years? Clin Endocrinol 2013; 78: 153-4.
[68]
Krarup T, Krarup T, Hagen C. Do patients with type 2 diabetes mellitus have an increased prevalence of Cushing’s syndrome? Diabetes Metab Res Rev 2012; 28(3): 219-27.
[69]
De Leo M, Cozzolino A, Colao A, Pivonello R. Subclinical Cushings syndrome. Best Pract Res Clin Endocrinol Metab 2016; 26(4): 497-505.
[70]
Reimondo G, Pia A, Allasino B, et al. Screening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus. Clin Endocrinol (Oxf) 2007; 67(2): 225-9.
[71]
Valassi E, Tabarin A, Brue T, et al. Diabetes mellitus and muscle weakness are independently associated with mortality in patients with Cushing’s syndrome. Data from ERCUSYN. Endocrine Abstr 2018; 56: 12-5.
[72]
Mazziotti G, Formenti AM, Frara S, Maffezzoni F, Doga M, Giustina A. Diabetes in Cushing Disease. Curr Diab Rep 2017; 17: 32.
[73]
Felšöci M, Schroner Z, Petrovičová J, Lazúrová I. Relationship between type 2 diabetes mellitus and hypothalamic-pituitary-adrenal axis. Wien Klin Wochenschr 2011; 123(1): 28-33.
[74]
Resmini E, Minuto F, Colao A, Ferone D. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol 2009; 46(2): 85-95.
[75]
Zimmermann A, Weber M. Hypophysenstorungen und sekundarer Diabetes mellitus. Der Diabetol 2010; 6(1): 29-36.
[76]
Reinehr T, Andler W. Cortisol and its relation to insulin resistance before and after weight loss in obese children. Horm Res 2004; 62(3): 107-12.
[77]
Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis. J Clin Endocrinol Metab 2009; 94: 2692-701.
[78]
Reynolds RM, Syddall HE, Walker BR, Wood PJ, Phillips DIW. Predicting cardiovascular risk factors from plasma cortisol measured during oral glucose tolerance tests. Metab - Clin Exp 2017;
52(5): 524-7.
[79]
Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88(6): 2527-33.
[80]
Connell JM, Whitworth JA, Davies DL, Lever AF, Richards AM, Fraser R. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 1987; 5(4): 425-33.
[81]
Ferrau F, Korbonits M. Metabolic syndrome in Cushing syndrome patients. In: Metabolic Syndrome Consequent to Endocrine Disorders. Popovic V, Korbonits M, Eds. Front Horm Res Karger: Basel
2018; vol 49, pp. 85-103.
[82]
Benker G, Raida M, Olbricht T, Wagner R, Reinhardt W, Reinwein D. TSH secretion in Cushing’s syndrome: relation to glucocorticoid excess, diabetes, goitre, and the ‘sick euthyroid syndrome’. Clin Endocrinol (Oxf) 1990; 33(6): 777-86.
[83]
Iwasaki Y, Takayasu S, Nishiyama M, et al. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11β-hydroxysteroid dehydrogenase type 1) gene. Mol Cell Endocrinol 2008; 285(1-2): 10-8.
[84]
Baid SK, Rubino D, Sinaii N, Ramsey S, Frank A, Nieman LK. Specificity of screening tests for cushing’s syndrome in an overweight and obese population. J Clin Endocrinol Metab 2009; 94(10): 3857-64.
[85]
Fierabracci P, Pinchera A, Martinelli S, et al. Prevalence of endocrine diseases in morbidly obese patients scheduled for bariatric surgery: Beyond diabetes. Obes Surg 2011; 21(1): 54-60.
[86]
Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JMC. Cortisol Effects on Body Mass, Blood Pressure, and Cholesterol in the General Population. Hypertension 1999; 33(6): 1364-8.
[87]
Qin L, Zhu X, Liu X, et al. Evaluation of lipid profile and its relationship with blood pressure in patients with Cushing’s disease. Endocr Connect 2018; 7(5): 637-44.
[88]
Salih M. Urinary extracellular vesicles: Biomarkers and beyond.
PhD dissertation. Erasmus Universiteit Rotterdam 2017.
[89]
Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M. Pathophysiology of dyslipidemia in Cushing’s syndrome. Neuroendocrinol 2010; 92(Suppl. 1): 86-90.
[90]
Morgan SA, Hassan-Smith ZK, Lavery GG. Mechanisms in endocrinology: Tissue-specific activation of cortisol in Cushing’s syndrome. Eur J Endocrinol 2016; 175(2): R83-9.
[91]
Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2007; 28(19): 2375-414.
[92]
Koutroumpi S, Daidone V, Sartori MT, et al. Venous thromboembolism in patients with Cushing’s syndrome: Need of a careful investigation of the prothrombotic risk profile. Pituitary 2013; 16(2): 175-81.
[93]
Terzolo M, Allasino B, Bosio S, et al. Hyperhomocysteinemia in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2004; 89(8): 3745-51.
[94]
Jacoby RC, Owings JT, Ortega T, Gosselin R, Feldman EC. Biochemical basis for the hypercoagulable state seen in Cushing syndrome; discussion 1006-7. Arch Surg 2001; 136(9): 1003-6.
[95]
Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994; 40(4): 479-84.
[96]
Boscaro M, Sonino N, Scarda A, et al. Anticoagulant Prophylaxis Markedly Reduces Thromboembolic Complications in Cushing’s Syndrome. J Clin Endocrinol Metab 2002; 87(8): 3662-6.
[97]
Diez JJ, Iglesias P. Pulmonary thromboembolism after inferior petrosal sinus sampling in Cushing’s syndrome. Clin Endocrinol (Oxf) 1997; 46(6): 777.
[98]
Obuobie K, Davies JS, Ogunko A, Scanlon MF. Venous thrombo-embolism following inferior petrosal sinus sampling in Cushing’s disease. J Endocrinol Invest 2000; 23(8): 542-4.
[99]
Giri S, Mehta KD, Bhatt VB. Secondary Polycythemia and the risk of Venous Thromboembolism (VTE) among hospitalized patients in the United States. Blood 2016; 128: 1427.
[100]
Nwose EU. Whole blood viscosity assessment issues II: Prevalence in endothelial dysfunction and hypercoagulation. N Am J Med Sci 2010; 2(6): 252-7.
[101]
Baykan M, Erem C, Gedikli Ö, et al. Impairment in flow-mediated vasodilatation of the brachial artery in acromegaly. Med Princ Pract 2009; 18(3): 228-32.
[102]
Albiger N, Testa RM, Almoto B, et al. Patients with Cushing’s syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. Horm Metab Res 2006; 38(6): 405-10.
[103]
Evran M, Akkuş G, Berk Bozdoğan İ, et al. Carotid intima-media thickness as the cardiometabolic risk indicator in patients with nonfunctional adrenal mass and metabolic syndrome screening. Med Sci Monit 2016; 22: 991-7.
[104]
Petramala L, Lorenzo D, Iannucci G, et al. Subclinical atherosclerosis in patients with cushing syndrome: Evaluation with carotid intima-media thickness and ankle-brachial index. Endocrinol Metab (Seoul) 2015; 30(4): 488-93.
[105]
Giannopoulos A, Kakkos S, Abbott A, et al. Long-term mortality in patients with asymptomatic carotid stenosis: Implications for statin therapy. Eur J Vasc Endovasc Surg 2015; 50: 573-82.
[106]
Ma RCW, So WY, Tong PCY, Chan JCN, Cockram CS, Chow CC. Adiposity of the heart revisited: Reversal of dilated cardiomyopathy in a patient with Cushing’s syndrome. Int J Cardiol 2017; 151(1): e22-3.
[107]
Muiesan ML, Lupia M, Salvetti M, et al. Left ventricular structural and functional characteristics in Cushing’s syndrome. J Am Coll Cardiol 2003; 41(12): 2275-9.
[108]
Gonzaga CC, Gaddam KK, Ahmed MI, et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med 2010; 6(4): 363-8.
[109]
Bottini P, Tantucci C. Sleep apnea syndrome in endocrine diseases. Respiration 2003; 70(3): 320-7.
[110]
Spiegel K, Tasali E, Leproult R, Van Cauter E. Effects of poor and short sleep on glucose metabolism and obesity risk. Nat Rev Endocrinol 2009; 5(5): 253-61.
[111]
Zilio M, Mazzai L, Sartori MT, et al. A venous thromboembolism risk assessment model for patients with Cushing’s syndrome. Endocrine 2016; 52(2): 322-32.
[112]
Dekkers OM, Horváth-Puhó E, Jørgensen JO, et al. Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab 2013; 98(6): 2277-84.
[113]
Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond) 2018; 18(3): 245-50.
[114]
Ragucci E, Nguyen D, Lamerson M, Moraitis AG. Effects of Mifepristone on Nonalcoholic Fatty Liver Disease in a Patient with a Cortisol-Secreting Adrenal Adenoma. Case Rep Endocrinol 2017; 20176161348
[115]
Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932; 50: 137-95.
[116]
Pivonello R, Simeoli C, De Martino MC, et al. Neuropsychiatric disorders in Cushing’s syndrome. Front Neurosci 2015; 9: 129.
[117]
Sonino N, Fava GA. Psychiatric disorders associated with Cushing’s syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 2001; 15(5): 361-73.
[118]
Bratek A, Koźmin-Burzyńska A, Górniak E, Krysta K. Psychiatric disorders associated with Cushing’s syndrome. Psychiatr Danub 2015; 27(Suppl. 1): S339-43.
[119]
Santos A, Resmini E, Pascual JC, Crespo I, Webb SM. Psychiatric Symptoms in Patients with Cushing’s Syndrome: Prevalence, Diagnosis and Management. Drugs 2017; 77(8): 829-42.
[120]
Manolis AA, Manolis TA, Mikhailidis DP, Manolis AS. Cardiovascular safety of oncologic agents: double-edged sword even in the era of targeted therapies – Part 1. Expert Opin Drug Saf 2018; 17(9): 875-92.
[121]
Manolis AA, Manolis TA, Mikhailidis DP, Manolis AS. Cardiovascular safety of oncologic agents: double-edged sword even in the era of targeted therapies – Part 2. Expert Opin Drug Saf 2018; 17(9): 893-15.
[122]
Smets P, Meyer E, Maddens B, Daminet S. Cushing’s syndrome, glucocorticoids and the kidney. Gen Comp Endocrinol 2010; 169(1): 1-10.
[123]
Janicki-Deverts D, Cohen S, Turner RB, Doyle WJ. Basal salivary cortisol secretion and susceptibility to upper respiratory infection. Brain Behav Immun 2016; 53: 255-61.
[124]
Lonser RR, Nieman L, Oldfield EH. Cushing’s disease: pathobiology, diagnosis, and management. J Neurosurg 2017; 126(2): 404-17.
[125]
Ioachimescu AG. Cushing’s Syndrome 2018: Best Practices and Looking Ahead. Endocrinol Metab Clin North Am 2018; 47(2): xiii-v.
[126]
Pires P, Santos A, Vives-Gilabert Y, et al. White matter alterations in the brains of patients with active, remitted, and cured cushing syndrome: a DTI study. AJNR Am J Neuroradiol 2015; 36(6): 1043-8.
[127]
Berr CM, Stieg MR, Deutschbein T, et al. Persistence of myopathy in Cushing’s syndrome: evaluation of the German Cushing’s Registry. Eur J Endocrinol 2017; 176(6): 737-46.
[128]
Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jørgensen JO. Mortality in Cushing’s syndrome: a systematic review and meta-analysis. Eur J Intern Med 2012; 23(3): 278-82.
[129]
Ntali G, Asimakopoulou A, Siamatras T, et al. Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 2013; 169(5): 715-23.
[130]
Yaneva M, Kalinov K, Zacharieva S. Mortality in Cushing’s syndrome: data from 386 patients from a single tertiary referral center. Eur J Endocrinol 2013; 169(5): 621-7.
[131]
Durrani WRK, Ali Z, Shafi T, Iqbal MD. Iatrogenic Cushing syndrome: A neglected aspect of medical care. Pak J Surg 2017; 33(3): 199-202.
[133]
Pektas SD, Dogan G, Cinar N. Iatrogenic Cushing’s syndrome with subsequent adrenal insufficiency in a patient with psoriasis vulgaris using topical steroids. Case Rep Endocrinol 2017.8320254
[134]
Aulinas A, Ramírez MJ, Barahona MJ, et al. Dyslipidemia and chronic inflammation markers are correlated with telomere length shortening in Cushing’s syndrome. PLoS One 2015; 10(3)e0120185
[135]
Uzu T, Harada T, Sakaguchi M, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract 2007; 105(2): c54-7.
[136]
Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009; 15(5): 469-74.
[137]
Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: A systematic review and network meta-analysis. JAMA Cardiol 2017; 2(7): 775-81.
[138]
Hermida RC, Ayala DE, Fernández JR, Mojón A, Smolensky MH. Hypertension: New perspective on its definition and clinical management by bedtime therapy substantially reduces cardiovascular disease risk. Eur J Clin Invest 2018; 48(5)e12909
[139]
Barkas F, Elisaf M. National hyperlipidemia management policies improve lipid target attainment in clinical practice. Curr Med Res Opin 2018; 34(2): 301-3.
[140]
Andersson T, Hjerpe P, Carlsson AC, et al. Mortality trends and cause of death in patients with new-onset type 2 diabetes and controls: A 24-year follow-up prospective cohort study. Diabetes Res Clin Pract 2018; 138: 81-9.
[141]
Patel SA, Winkel M, Ali MK, Narayan KM, Mehta NK. Cardiovascular mortality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data. Ann Intern Med 2015; 163(4): 245-53.
[142]
Lee SW, Son JY, Kim JM, Hwang SS, Han JS, Heo NJ. Body fat distribution is more predictive of all-cause mortality than overall adiposity. Diabetes Obes Metab 2018; 20(1): 141-7.
[143]
Cansu GB, Atılgan S, Balcı MK, Sarı R, Özdem S, Altunbaş HA. Which type 2 diabetes mellitus patients should be screened for subclinical Cushing’s syndrome? Hormones (Athens) 2017; 16(1): 22-32.
[144]
Yanase T, Oki Y, Katabami T, et al. New diagnostic criteria of adrenal subclinical Cushing’s syndrome: opinion from the Japan Endocrine Society. Endocr J 2018; 65(4): 383-93.
[145]
Anagnostis P, Karras SN, Athyros VG, Mikhailidis DP, Karagiannis A. Subclinical Cushing’s syndrome and cardiovascular disease. Lancet Diabetes Endocrinol 2014; 2(5): 361.
[146]
Bancos I, Alahdab F, Crowley RK, et al. Therapy of endocrine disease: Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing’s syndrome: a systematic review and meta-analysis. Eur J Endocrinol 2016; 175(6): R283-95.
[147]
Paschou SA, Kandaraki E, Dimitropoulou F, Goulis DG, Vryonidou A. Subclinical Cushing’s syndrome in patients with bilateral compared to unilateral adrenal incidentalomas: a systematic review and meta-analysis. Endocrine 2016; 51(2): 225-35.
[148]
Pappachan JM, Hariman C, Edavalath M, Waldron J, Hanna FW. Cushing’s syndrome: a practical approach to diagnosis and differential diagnoses. J Clin Pathol 2017; 70(4): 350-9.
[149]
Morelli V, Palmieri S, Lania A, et al. Cardiovascular events in patients with mild autonomous cortisol secretion: analysis with artificial neural networks. Eur J Endocrinol 2017; 177(1): 73-83.
[150]
Wilson MC, Hayward RS, Tunis SR, Bass EB, Guyatt G. Users’ guides to the Medical Literature. VIII. How to use clinical practice guidelines. B. what are the recommendations and will they help you in caring for your patients? The Evidence-Based Medicine Working Group. JAMA 1995; 274(20): 1630-2.
[151]
Kruger J, O’Halloran A, Rosenthal A. Assessment of compliance with U.S. Public Health Service clinical practice guideline for tobacco by primary care physicians. Harm Reduct J 2015; 12: 7.
[152]
Kulczycki A, Qu H, Shewchuk R. Primary Care Physicians’ Adherence to Guidelines and Their Likelihood to Prescribe the Human Papillomavirus Vaccine for 11- and 12-Year-Old Girls. Womens Health Issues 2016; 26(1): 34-9.
[153]
Dalbeth N, Bardin T, Doherty M, et al. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol 2017; 13(9): 561-8.
[154]
Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282(15): 1458-65.
[155]
Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002; 19(6): 596-604.
[156]
Heppner HJ, Singler K, Kwetkat A, et al. Do clinical guidelines improve management of sepsis in critically ill elderly patients? A before-and-after study of the implementation of a sepsis protocol. Wien Klin Wochenschr 2012; 124(19-20): 692-8.
[157]
Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet 2014; 383(9921): 999-1008.
[158]
Tsao CW, Vasan RS. Cohort Profile: The Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology. Int J Epidemiol 2015; 44(6): 1800-13.
[159]
Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes 2014; 5(4): 444-70.
[160]
Conroy RM, Pyörälä K, Fitzgerald AP, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24(11): 987-1003.
[161]
Authors/Task Force Members:, Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 252: 207-74.
[162]
Lloyd-Jones DM, Wilson PW, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004; 94(1): 20-4.
[163]
Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206-52.
[164]
Lupoli R, Ambrosino P, Tortora A, Barba L, Lupoli GA, Di Minno MN. Markers of atherosclerosis in patients with Cushing’s syndrome: a meta-analysis of literature studies. Ann Med 2017; 49(3): 206-16.
[165]
Witek P, Zieliński G, Szamotulska K, Witek J, Kamiński G. Cushing’s disease: Fibrinogen and D-dimer levels fail to normalize despite early postoperative remission - a prospective, controlled study. Endokrynol Pol 2016; 67(3): 283-91.
[166]
Santos A, Resmini E, Gómez-Ansón B, et al. Cardiovascular risk and white matter lesions after endocrine control of Cushing’s syndrome. Eur J Endocrinol 2015; 173(6): 765-75.
[167]
Boero L, Manavela M, Botta E, et al. Conditioning factors for high cardiovascular risk in patients with Cushing syndrome. Endocr Pract 2015; 21(7): 734-42.
[168]
Isidori AM, Graziadio C, Paragliola RM, et al. ABC Study Group. The hypertension of Cushing’s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens 2015; 33(1): 44-60.
[169]
Osswald A, Deutschbein T, Berr CM, et al. Surviving ectopic Cushing’s syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushing’s disease during long-term follow-up. Eur J Endocrinol 2018; 179(2): 109-16.
[170]
Webb SM, Valassi E. Morbidity of Cushing’s Syndrome and Impact of Treatment. Endocrinol Metab Clin North Am 2018; 47(2): 299-311.
[171]
Frustaci A, Letizia C, Chimenti C. Morphologic and molecular pathway of Cushing syndrome cardiomyopathy. Endocrine 2018; 60(2): 372.
[172]
Javanmard P, Duan D, Geer EB. Mortality in Patients with Endogenous Cushing’s Syndrome. Endocrinol Metab Clin North Am 2018; 47(2): 313-33.
[173]
Yorke E, Atiase Y, Akpalu J, Sarfo-Kantanka O. Screening for Cushing Syndrome at the Primary Care Level: What Every General Practitioner Must Know. Int J Endocrinol 2017.1547358
[174]
Geer EB, Shafiq I, Gordon MB, et al. Biochemical control during long-term follow-up of 230 adult patients with Cushing disease: a multicenter retrospective study. Endocr Pract 2017; 23(8): 962-70.
[175]
Yiu KH, Marsan NA, Delgado V, et al. Increased myocardial fibrosis and left ventricular dysfunction in Cushing’s syndrome. Eur J Endocrinol 2012; 166(1): 27-34.
[176]
Nieman LK, Biller BMK, Findling JW, et al. The Diagnosis of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93(5): 1526-40.
[177]
Krikorian A, Khan M. Is metabolic syndrome a mild form of Cushing’s syndrome? Rev Endocr Metab Disord 2010; 11(2): 141-5.
[178]
Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23(2): 168-75.
[179]
Ferroni P, Basili S, Paoletti V, Davì G. Endothelial dysfunction and oxidative stress in arterial hypertension. Nutr Metab Cardiovasc Dis 2006; 16(3): 222-33.
[180]
Virdis A, Colluci R, Bernardini N, Blandizzi C, Taddei S, Masi S. Microvascular endothelial dysfunction in human obesity: Role of TNF-α. J Clin Endocrinol Metab 2019; 104(2): 341-8.
[181]
Saad JAM. Obesity, Diabetes, and Endothelium: Molecular Interactions. In: Vascular Biology and Clinical Syndromes Da Luz P. Libby P, Chagas A, Laurindo F. Eds. Academic Press: Waltham,
Massachusetts 2018; pp. 639-52.
[182]
Moreno B, de Faria AP, Ritter AMV, et al. Glycated hemoglobin correlates with arterial stiffness and endothelial dysfunction in patients with resistant hypertension and uncontrolled diabetes mellitus. J Clin Hypertens (Greenwich) 2018; 20(5): 910-7.
[183]
Mudau M, Genis A, Lochner A, Strijdom H. Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc J Afr 2012; 23(4): 222-31.
[184]
Harrison DG. From ST segments to endothelial pathophysiology: hypercholesterolemia and endothelial superoxide production. J Clin Invest 2014; 124(2): 473-5.
[185]
Wagenmakers MA, Roerink SH, Schreuder TH, et al. Vascular Health in Patients in Remission of Cushing’s Syndrome Is Comparable With That in BMI-Matched Controls. J Clin Endocrinol Metab 2016; 101(11): 4142-50.
[186]
Aranda G, Fernandez-Ruiz R, Palomo M, et al. Translational evidence of prothrombotic and inflammatory endothelial damage in Cushing syndrome after remission. Clin Endocrinol (Oxf) 2018; 88(3): 415-24.
[187]
Ras RT, Streppel MT, Draijer R, Zock PL. Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. Int J Cardiol 2013; 168(1): 344-51.
[188]
Cardona A, Kondapally Seshasai SR, Davey J, et al. A meta-analysis of published studies of endothelial dysfunction does not support its routine clinical use. Int J Clin Pract 2015; 69(6): 649-58.
[189]
Battocchio M, Rebellato A, Grillo A, et al. Ambulatory Arterial Stiffness Indexes in Cushing’s Syndrome. Horm Metab Res 2017; 49(3): 214-20.
[190]
Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 2015; 241(2): 507-32.
[191]
Doonan RJ, Hausvater A, Scallan C, Mikhailidis DP, Pilote L, Daskalopoulou SS. The effect of smoking on arterial stiffness. Hypertens Res 2010; 33(5): 398-410.
[192]
Younge PA, Shmidt D, Wiles PG. Cushing’s syndrome: still a potential killing disease. J R Soc Med 1995; 88(3): 174P-5P.
[193]
Smith SC, Allen J, Blair SN, et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Circulation 2006; 113(19): 2363-72.
[194]
Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. Circulation 2002; 106(3): 388-91.
[195]
Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27(11): 2121-58.
[196]
Whitworth JA. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21(11): 1983-92.
[197]
Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2013; 34(39): 3035-87.
[198]
Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation 2014; 129(25)(Suppl. 2): S102-38.
[199]
Go AS, Bauman MA, Coleman King SM, et al. An Effective Approach to High Blood Pressure Control. Hypertension 2014; 63(4): 878-85.
[200]
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation 2014; 129(25)(Suppl. 2): S1-S45.
[201]
Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014; 63(25 Pt B): 2960-84.
[202]
Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation 2014; 129(25 Suppl 2): S49-73.
[203]
Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease an American heart association/American college of cardiology foundation scientific statement from the American heart association council for high blood pressure research professional education committee, council on Cl. J Am Coll Cardiol 2008; 52(8): 686-717.
[204]
British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(Suppl. 5): v1-v52.
[205]
SIGN 149 • Risk estimation and the prevention of cardiovascular
disease, A national clinical guideline. 2017. [Available from: https://www.sign.ac.uk/sign-149-risk-estimation-and-the-prevention-of-cardiovascular-disease.html
Call for Papers in Thematic Issues
31 January, 2025
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Anthocyanins: Pharmacology and Nutraceutical Importance
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
The Role of Chromenes in Drug Discovery and Development
Article Metrics
22
2